Wart Remover

Description

Papilofag is a topical wart remover formulated for the treatment of common warts. It is presented in a 0.5 fluid ounce (15 mL) dosage form. The product is designed to effectively target and eliminate warts through its active ingredients.

Uses and Indications

This drug is indicated for the removal of warts.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

Healthcare professionals are advised to follow the outlined procedure for the application of the treatment to ensure optimal results.

The affected area should be washed thoroughly and dried completely before application. Using the provided applicator, one drop of the treatment should be applied at a time to ensure sufficient coverage of each wart. After application, the area should be allowed to dry.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated skin is prohibited due to the potential for exacerbating the condition. The product should not be applied to any area that is infected or reddened, as this may lead to further irritation or complications.

Patients with diabetes should avoid use, as the risk of impaired healing may be increased. Additionally, individuals with poor blood circulation are contraindicated from using this product due to the potential for inadequate tissue perfusion and healing.

The product must not be applied to moles, birthmarks, or warts with hair growing from them, as well as genital warts or warts located on the face or mucous membranes, due to the risk of adverse reactions or complications in these sensitive areas.

Warnings and Precautions

For external use only. This product is flammable; it must be kept away from fire and flame to prevent any risk of ignition.

The product should not be applied to irritated skin or any area that is infected or reddened. It is contraindicated for use in individuals with diabetes or those who have poor blood circulation. Additionally, it should not be used on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes.

Healthcare professionals should advise patients to discontinue use and consult a physician if discomfort persists.

In the event of accidental ingestion, it is imperative to seek emergency medical assistance or contact a Poison Control Center immediately.

Side Effects

Patients should be aware that the product is for external use only and is flammable; it should be kept away from fire and flame. The product should not be applied to irritated skin, infected or reddened areas, or on moles, birthmarks, warts with hair growing from them, genital warts, or warts on the face or mucous membranes. Additionally, it is contraindicated for use in individuals who are diabetic or have poor blood circulation.

In the event that discomfort persists, patients are advised to stop use and consult a healthcare professional.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

There is currently no information available regarding the use of WART REMOVER (salicylic acid solution) during pregnancy. As such, the safety of this medication in pregnant patients has not been established, and there are no known dosage modifications or special precautions recommended for use in this population. Healthcare professionals should weigh the potential benefits against any unknown risks when considering treatment options for women of childbearing potential. It is advisable to discuss alternative therapies with pregnant patients or those planning to become pregnant.

Lactation

There are no specific warnings or recommendations regarding the use of this medication in nursing mothers. Additionally, there are no specific warnings or recommendations related to lactation. Healthcare professionals should consider the absence of data when advising lactating mothers on the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted in these patients to ensure safety and therapeutic effectiveness.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, and respiratory distress.

In the event of an overdose, immediate medical intervention is recommended. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and is deemed appropriate based on clinical judgment.

Furthermore, it is crucial to consult local poison control centers or toxicology experts for guidance on specific management protocols and antidotes, if applicable. Continuous assessment and supportive measures should be prioritized to ensure patient safety and mitigate potential complications associated with overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

No postmarketing experience details are available in the provided data.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children. In the event of accidental ingestion, patients should seek medical assistance or contact a Poison Control Center immediately.

Patients should be informed to discontinue use and consult a doctor if discomfort persists. When using the product, it is important to ensure that the bottle is capped tightly after each use. In case the product comes into contact with the eyes, patients should flush the eyes with water for at least 15 minutes. Additionally, patients should be cautioned to avoid inhaling vapors associated with the product.

Storage and Handling

The product is supplied in packaging that includes an NDC number for identification. It should be stored at room temperature, ensuring it is kept away from heat sources to maintain its integrity. Healthcare professionals are advised to inspect the product prior to use; it should not be used if the seal over the cap is torn or missing, as this may compromise the product's safety and efficacy.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)